With only 11 weeks to go and already over 100 experts confirmed to attend, this year’s audience warrants one of our most dynamic and engaged gatherings yet!
Despite turbulence with unexpected failures rocking the industry, the overwhelming response from the community shows the dedication of drug developers to advance treatment options for IPF patients in need.
This week only you can ð˜€ð—®ð˜ƒð—² ð˜‚ð—½ ð˜ð—¼ $ðŸ³ðŸ¬ðŸ¬ on your registration to the ðŸ´ð˜ð—µ ð—œð—£ð—™ ð—¦ð˜‚ð—ºð—ºð—¶ð˜ ðŸ®ðŸ¬ðŸ®ðŸ°, and that doesn’t include the discounts for bringing a colleague! ð—›ð˜‚ð—¿ð—¿ð˜†, ð˜ð—µð—¶ð˜€ ð—±ð—¶ð˜€ð—°ð—¼ð˜‚ð—»ð˜ ð—²ð˜…ð—½ð—¶ð—¿ð—²ð˜€ ð—™ð—¿ð—¶ð—±ð—®ð˜†, ð—ð˜‚ð—»ð—² ðŸ³!
View the program here:Â https://ter.li/r7shqs
Register here:Â https://ter.li/cpcvjd
Â
What’s in store?
🔹 Two dedicated tracks (ð—˜ð—ºð—²ð—¿ð—´ð—¶ð—»ð—´ ð—•ð—¶ð—¼ð—¹ð—¼ð—´ð˜† & ð—˜ð—®ð—¿ð—¹ð˜† ð—§ð—¿ð—®ð—»ð˜€ð—¹ð—®ð˜ð—¶ð—¼ð—» and ð—Ÿð—®ð˜ð—² ð—§ð—¿ð—®ð—»ð˜€ð—¹ð—®ð˜ð—¶ð—¼ð—» & ð—–ð—¹ð—¶ð—»ð—¶ð—°ð—®ð—¹) featuring unmissable content, from leveraging the latest advancements in Pulmonary Fibrosis recapitulation to enhance preclinical modelling to evolving measures of progress: surrogate, exploratory and composite endpoints for earlier detection of clinical benefit
🔹 Return of the highly anticipated ð—”ð—ºð—¯ð—®ð˜€ð˜€ð—®ð—±ð—¼ð—¿ð˜€ ð—˜ð˜ƒð—²ð—»ð—¶ð—»ð—´ ð——ð—¿ð—¶ð—»ð—¸ð˜€ ð—¥ð—²ð—°ð—²ð—½ð˜ð—¶ð—¼ð—» allowing you to interrogate recent failures by dissecting targets, MOA, chosen biomarkers, endpoints, patient populations and beyond to learn and take lessons learned into current therapeutic development
🔹 ð—£ð—¿ð—²ð˜€ð—²ð—»ð˜ ð˜†ð—¼ð˜‚ð—¿ ð—¼ð˜„ð—» ð—¿ð—²ð˜€ð—²ð—®ð—¿ð—°ð—µ and developments at our exclusive poster session, gain visibility, demonstrate your thought leadership, and receive important feedback all whilst attracting the attention of industry stakeholders
🔹 Plus ðŸ°ðŸ¬+ expert speakers, ðŸ´+ hours of face-to-face networking, 🲠interactive discussion-based workshops + ð—ºð—¼ð—¿ð—²
As the largest gathering of IPF professionals, this is a must-attend event for all IPF enthusiasts looking to propel innovative and efficacious pulmonary fibrosis therapeutics through phase 2 and beyond.
🔹 ð——ð—¼ð—»â€™ð˜ ð—³ð—¼ð—¿ð—´ð—²ð˜ – ð˜ð—µð—¶ð˜€ ð—™ð—¿ð—¶ð—±ð—®ð˜† ð—ð˜‚ð—»ð—² 🳠ð—¶ð˜€ ð˜†ð—¼ð˜‚ð—¿ ð—¹ð—®ð˜€ð˜ ð—°ð—µð—®ð—»ð—°ð—² ð˜ð—¼ ð˜€ð—®ð˜ƒð—² ð˜‚ð—½ ð˜ð—¼ $ðŸ³ðŸ¬ðŸ¬ ð—¼ð—» ð˜†ð—¼ð˜‚ð—¿ ð—¿ð—²ð—´ð—¶ð˜€ð˜ð—¿ð—®ð˜ð—¶ð—¼ð—»! Register here: https://ter.li/cpcvjd
Adam Freund, Aditya Patel, Ahmed Mousa, Amy Case, Professor Bertil E. Lindmark, Bhavika Kaul,, Brian Windsor, Carmel Nanthakumar, Claire Emson, Kotton, Darrell, David Lagares, David Rowlands, Elaine Kilgour, Farida Ahangari, ð—™ð—²ð—¿ð—»ð—®ð—»ð—±ð—¼ ð— ð—®ð—¿ð˜ð—¶ð—»ð—²ð˜‡, Gregory Cosgrove, Henrik Landgren, Imran Alibhai, Imre Noth, Ines Macias-Perez,, Jason McCarthy,, Jeffrey Bornstein, Jim Wu, Joe GN "Skip" Garcia,, Katie M., Kjetil Ask, Lee Borthwick, Lida Hariri, ð— ð—®ð—¿ð—´ð—®ð—¿ð—²ð˜ ð—¦ð—®ð—¹ð—¶ð˜€ð—¯ð˜‚ð—¿ð˜†, marilyn glassberg, Matthew Thomas, Peter George, Peter Smith, Piet Wigerinck, Steven Greenberg, ð—¦ð˜†ð—±ð—»ð—²ð˜† ð— ð—¼ð—»ð˜ð—²ð˜€ð—¶, Thomas Fabre, Tim Oldham, Toby Maher, Vipin Kumar, Zbigniew Zaslona
